Best in Biotech 13 Mar 2025 Nine biotechs thriving in Seattle in 2025 In this article, let us take a look at some of the major biotech companies in Seattle that are contributing to the biotech industry at large. March 13, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 18 Feb 2025 T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments T cell engagers represent a novel approach to tuning the immune system to target and kill tumor cells, expanding treatment options for cancer. February 18, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 12 Feb 2025 Dendritic cell therapy: Diakonos, Northwest Biotherapeutics and Mendus push ahead with next-generation candidates Find out about the field of dendritic cell therapy, as several companies attempt to bring next-generation candidates through the clinic. February 12, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 31 Oct 2024 Five T cell engager companies you should know about Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off. October 31, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
More News! 4 Dec 2023 FDA CAR-T cell therapy warning: Are T cells malignant? Chimeric antigen receptor (CAR) T cell therapies have emerged as groundbreaking treatments for various hematologic cancers, demonstrating remarkable efficacy in targeting specific cancer cells. However, recent concerns raised by the U.S. Food and Drug Administration (FDA) have sparked an investigation into potential risks associated with these therapies. The FDA CAR-T cell therapy warning comes at […] December 4, 2023 - 4 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 8 Sep 2023Beyond Biotech podcast 62 – cytokine-based drugs As September 8 is Stand Up To Cancer Day, one area of promising research lies in cytokine-based drugs, which have the potential to activate T cells against tumors. Historically, toxicity from systemic cytokine treatment has remained a challenge, prompting several companies to explore ways to “engineer” drugs with modified cytokine molecules like interleukin 2 (IL-2) […] September 8, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2023 Crescendo Biologics raises $32M and expands cancer trial Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, has announced that it plans to augment the ongoing phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major […] July 25, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 CatalYm shows importance of GDF-15 in tumor immunotherapy resistance CatalYm has published preclinical data in Nature Communications that reveal the central role of Growth Differentiation Factor-15 (GDF-15) in the resistance of tumors to current immunotherapy. CatalYm said the findings further highlight the therapeutic significance of its proprietary anti-GDF-15 antibody candidate, visugromab, currently in advanced phase 2 clinical studies. The foundational research, which was performed […] July 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2023 CytoMed Therapeutics receives US patent for CAR-Gamma Delta T-cell technology CytoMed Therapeutics Limited, a Singapore-based biopharma company focused on novel donor cell-based immunotherapies for the treatment of various cancers, has announced that its CAR-gamma delta T cell (CAR-γδ T cell) technology, which it has licensed from A*STAR, has been granted a patent by the US Patent and Trademark Office (USPTO). The patent covers technologies for […] July 7, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2023 FDA clears T-Cell receptor natural killer cell therapy for sarcoma Replay, a genome writing company, and The University of Texas MD Anderson Cancer Center (MD Anderson), have announced that the U.S. Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T-cell receptor natural killer (TCR-NK) cell therapy for advanced synovial […] June 21, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2023 IOME Bio claims breakthrough in cancer research IOME Bio, a French seed stage biotechnology company focused on overcoming tumor resistance to immune checkpoint inhibition, has published its foundational research by founders Arlene Sharpe and Dennis Kasper in Nature. The company said its work reveals unique insights into the critical importance of the RGMb/PD-L2 pathway in immunotherapy resistance and further strengthens the significance […] June 15, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2023 Sanofi drug reduces disease activity in relapsing MS New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a phase 2 trial of patients with relapsing multiple sclerosis (MS). Following 12 weeks of therapy, […] June 1, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email